Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha.

Matrix metalloproteinase-9 (MMP-9) is an important enzyme in tumor invasion and metastasis in malignant tumors, including cholangiocarcinoma (CC). Tumor necrosis factor-alpha (TNF-alpha), a proinflammatory cytokine, was recently reported to induce the up-regulation of MMP-9 in cultured CC cells. We examined whether cyclooxygenase-2 (COX-2) and prostaglandin-E2 (PGE2), another endogenous tumor promoter, are involved in the up-regulation of MMP-9 in CC using CC tissue specimens and a CC cell line, HuCCT-1. MMP-9 and COX-2 were immunohistochemically expressed in 58% and 89% of 110 CC cases, respectively; the expression of MMP-9 and COX-2 was correlated (r = 0.32, P = 0.00072). Using zymography, latent MMP-9 was detectable in all cases and active MMP-9 was detected in 24% of cases of the CC specimens. The TNF-alpha/TNF-receptor 1 (TNF-R1) interaction induced MMP-9 production and activation, as well as COX-2 overexpression and PGE2 production, and increased the migration of CC cells. MMP-9 up-regulation was inhibited by COX inhibitors, antagonists of EP2/4 (receptors of PGE2), and COX-1 and COX-2 siRNAs. Inhibitors of both MMP-9 and MMP-9 siRNA treatment abrogated the increase in the migration of CC cells induced by TNF-alpha. In conclusion, we propose a novel signaling pathway of MMP-9 up-regulation in CC cells such that TNF-alpha induces the activation of COX-2 and PGE2 via TNF-R1 followed by the up-regulation of MMP-9 via the PGE2 (EP2/4) receptor.

[1]  Y. Nakanuma,et al.  Over‐expression of polycomb group protein EZH2 relates to decreased expression of p16INK4a in cholangiocarcinogenesis in hepatolithiasis , 2008, The Journal of pathology.

[2]  G. Gores.  PERSPECTIVES IN CLINICAL HEPATOLOGY Cholangiocarcinoma: Current Concepts and Insights , 2003 .

[3]  L. Marnett,et al.  COX-2: a target for colon cancer prevention. , 2002, Annual review of pharmacology and toxicology.

[4]  J. Westermarck,et al.  Regulation of matrix metalloproteinase expression in tumor invasion , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Tong Wu.  Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. , 2005, Biochimica et biophysica acta.

[6]  T. Senga,et al.  A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1. , 2006, Cancer research.

[7]  Y. Nakanuma,et al.  Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas , 2006, Hepatology.

[8]  R. DuBois,et al.  Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor* , 2003, Journal of Biological Chemistry.

[9]  T. Terada,et al.  Are hepatolithiasis and cholangiocarcinoma aetiologically related? , 1985, Virchows Archiv A.

[10]  K. Schmid,et al.  Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma , 2006, Virchows Archiv.

[11]  Y. Nimura,et al.  Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. , 2006, The American journal of pathology.

[12]  A. Sirica,et al.  Biliary cancer growth factor pathways, cyclo‐oxygenase‐2 and potential therapeutic strategies , 2001, Journal of gastroenterology and hepatology.

[13]  H. Sato,et al.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. , 1993, Oncogene.

[14]  Nagorney Dm,et al.  Carcinoma of the gallbladder and extrahepatic bile ducts. , 1988 .

[15]  T. Terada,et al.  Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. , 1998, Human pathology.

[16]  A. Dannenberg,et al.  Targeting Prostaglandin E2 Receptors as an Alternative Strategy to Block Cyclooxygenase-2-dependent Extracellular Matrix-induced Matrix Metalloproteinase-9 Expression by Macrophages* , 2006, Journal of Biological Chemistry.

[17]  Y. Nakanuma,et al.  Relationship between interleukin‐6 and proliferation and differentiation in cholangiocarcinoma , 1998, Histopathology.

[18]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[19]  W C Willett,et al.  Aspirin and the risk of colorectal cancer in women. , 1995, The New England journal of medicine.

[20]  J. Foidart,et al.  Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. , 2002, Experimental cell research.

[21]  Y. Jan,et al.  Profiling of gene expression associated with hepatolithiasis by complementary DNA expression array. , 2003, International journal of oncology.

[22]  Hiroshi Sato,et al.  Substrate choice of membrane‐type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase‐2 levels , 2007, Cancer science.

[23]  Y. Nimura,et al.  Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[24]  M. Björklund,et al.  Gelatinase-mediated migration and invasion of cancer cells. , 2005, Biochimica et biophysica acta.

[25]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[26]  T. Aoki,et al.  Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. , 2006, International journal of molecular medicine.

[27]  M. Nagino,et al.  Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. , 2000, Journal of hepato-biliary-pancreatic surgery.

[28]  Y. Ikeda,et al.  Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. , 1999, Surgery.

[29]  M. Miyazaki,et al.  Cholangiocarcinoma: Recent progress. Part 2: Molecular pathology and treatment , 2002, Journal of gastroenterology and hepatology.

[30]  M. Nagino,et al.  Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. , 2008, Human pathology.

[31]  F. Ciardiello,et al.  Chronic inflammation and oxidative stress in human carcinogenesis , 2007, International journal of cancer.

[32]  Y. Jan,et al.  Tumor necrosis factor α promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2 , 2005 .

[33]  A. Tarnawski,et al.  Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.

[34]  T. Takada,et al.  Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. , 2002, Journal of hepato-biliary-pancreatic surgery.

[35]  Alphonse E. Sirica,et al.  Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy , 2005, Hepatology.

[36]  Y. Okada,et al.  Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors , 1996, Hepatology.

[37]  S. Kawasaki,et al.  Matrix metalloproteinase‐7 expression and biologic aggressiveness of cholangiocellular carcinoma , 2002, Cancer.

[38]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.

[39]  A. Demetris,et al.  Cyclooxygenase-2 Promotes Human Cholangiocarcinoma Growth , 2004, Cancer Research.

[40]  U. Shankavaram,et al.  Differential Regulation of Lipopolysaccharide-Induced Monocyte Matrix Metalloproteinase (MMP)-1 and MMP-9 by p38 and Extracellular Signal-Regulated Kinase 1/2 Mitogen-Activated Protein Kinases , 2003, The Journal of Immunology.

[41]  J. Engler,et al.  Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells. , 2001, Cancer research.

[42]  C. Kelly,et al.  Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer , 2004, British Journal of Cancer.

[43]  Y. Nakanuma,et al.  Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply , 1997, Microscopy research and technique.

[44]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.